Insulin resistance in women: PCOS, menopause and why the symptoms are not “just stress”

A woman’s metabolism is not a smaller copy of a man’s. Oestrogen, progesterone and the cycle itself influence insulin sensitivity significantly – and when something goes wrong, the earliest signs are cycle disruption, adult acne, hair growth, irritability and post-meal fatigue. That is why insulin resistance so often goes undiagnosed in women: the symptoms do not “look like diabetes”.

The cycle itself is an insulin-sensitivity compass

Across a healthy cycle, insulin sensitivity fluctuates significantly. It is higher in the follicular phase (between menses and ovulation) and lower in the luteal phase (between ovulation and the next period) – one reason many women crave sweets and feel drained in the second half of the cycle. When the cycle becomes irregular, extends beyond 35 days, or disappears entirely (outside of pregnancy, lactation or menopause), hyperinsulinaemia is often the driver (Diamanti-Kandarakis & Dunaif, Endocrine Reviews 2012).

PCOS is a mirror of insulin resistance

Polycystic ovary syndrome (PCOS) affects an estimated 10–13% of women of reproductive age. The 2023 international PCOS guideline (Teede et al.) is explicit: insulin resistance underlies more than 70% of cases. Excess insulin stimulates ovarian androgen production (testosterone, androstenedione), which disrupts ovulation and produces the classic picture:

• Irregular or absent cycles
• Adult acne, especially along the chin and jawline
• Hirsutism – hair on the upper lip, chin, abdomen, chest
• Scalp hair thinning in an androgenic pattern
• Weight gain preferentially around the waist
• Acanthosis nigricans – dark, velvety skin at the neck or armpits

Women with PCOS carry a 4-fold higher risk of type 2 diabetes and a 2-fold higher cardiovascular risk. Clinically, though, the metabolic side of PCOS often responds to lifestyle even more strongly than “ordinary” insulin resistance. In my practice a 12-week program frequently restores ovulation without medication.

Gestational diabetes is a warning, not an episode

A woman who has had gestational diabetes (GDM) carries a 7-fold higher risk of type 2 diabetes in the next 5–10 years (Kim et al., Diabetes Care 2002). It is the result of a metabolic “stress test” – pregnancy unmasked latent resistance that was already present. Every such woman should get HOMA-IR and HbA1c every 1–3 years, even if the pregnancy ended uneventfully.

Perimenopause: when “everything starts changing”

During perimenopause (usually 40–50) the effect of oestrogen tapers off. Oestrogen helps insulin direct glucose into muscle and preferentially deposits fat on hips and thighs rather than around the waist. As oestrogen falls, body composition shifts even without weight change: visceral fat rises, muscle mass declines. Stefanska et al. (Adv Clin Chem 2015) report that the prevalence of metabolic syndrome in women rises by ~60% after menopause (Mauvais-Jarvis, Biol Sex Differ 2015).

This is not “inevitable ageing”. This is precisely where strength training (2–3× a week), adequate protein (1.6–2.0 g/kg target weight), sleep architecture and carbohydrate quality make the largest difference. The first three years are still highly plastic and the effect size is much larger than later.